Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
BLTE Stock Chart & Stats
$178.33
-$1.45(-2.47%)
At close: 4:00 PM EST
$178.33
-$1.45(-2.47%)
Day’s Range― - ―
52-Week Range$49.00 - $200.00
Previous CloseN/A
Volume15.47K
Average Volume (3M)64.23K
Market Cap
$6.38B
Enterprise Value$6.22B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 27, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding37,514,630
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio63.44
Price to Book (P/B)13.21
Price to Sales (P/S)0.00
P/FCF Ratio-65.58
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-126.89
Forecast
1Y Price Target
$186.57Price Target Upside4.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Efficacy And SafetyPivotal Phase 3 DRAGON results met the primary endpoint by demonstrating a meaningful slowdown in retinal lesion growth compared with placebo and showed a favorable safety profile, strengthening prospects for uptake by specialists.
Financial Strength For CommercializationA significant public financing combined with existing cash resources provides a solid runway to advance regulatory filings and initial global commercialization efforts.
Regulatory DesignationsMultiple regulatory designations in key jurisdictions, including Breakthrough Therapy and Fast Track in the U.S. and Orphan Drug plus Sakigake in Japan, support an accelerated review pathway and deeper regulator engagement.
Bears Say
FDA Additional Trial RiskA potential FDA request for an additional confirmatory trial could delay U.S. market entry and raise development costs, weighing on near-term valuation.
Payer And Pricing RiskHigh expected treatment cost may create initial payer resistance and reimbursement hurdles despite the disease's rare pediatric designation.
Regulatory Precedent UncertaintyAbsence of prior approvals for Stargardt disease type 1 may complicate the regulatory pathway and increase uncertainty across major markets.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $49.00 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $6.38B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Mar 27, 2026 which is in 49 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Nov 10, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.488 by -$0.162.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.54.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 37,514,630 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.488. Following the earnings report the stock price went up 3.666%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$186.57 (4.62% Upside)
$186.57 (4.62% Upside)
Hedge Fund Trend
Increased
By 924.8K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
-32.30%
Trailing 12-Months
Asset Growth
32.07%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects significant regulatory progress and strong financial positioning through successful funding. However, these positives are counterbalanced by increased losses and rising expenses, primarily due to share-based compensation and trial costs.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$186.57
▲(4.62% Upside)
Technical Analysis
Denali Therapeutics
―
Kiniksa Pharmaceuticals
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---